Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Secutrelvir in Participants with COVID-19
jRCT2031260334Phase 3Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Secutrelvir arm with Placebo arm (2 arms). Primary endpoint: Time to first resolution of 14 COVID-19 symptoms through day 21. Started Jul 2026; status: recruiting.
02
Drugs
secutrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031260334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260334.